Multiple target points miRNA antisense nucleic acid technique

An antisense nucleotide and multi-target technology, applied in the field of antisense nucleotide technology, can solve the problems of single targeting and poor efficacy

Active Publication Date: 2008-02-13
HARBIN MEDICAL UNIVERSITY +1
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The present invention proposes a multi-target miRNA antisense nucleotide technology t...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple target points miRNA antisense nucleic acid technique
  • Multiple target points miRNA antisense nucleic acid technique

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0005] Specific embodiment one: In this embodiment, the multi-target miRNA antisense nucleotide technology passes through the following

[0006] Method realization: 1. Find miRNAs that can regulate key genes through gene chip screening or literature provision;

[0007] 2. According to the selected multiple target miRNAs, artificially synthesize the respective antisense nucleotide chains of the selected target miRNAs, which are called antisense units; 3. Design the antisense units of different target miRNAs into one that can simultaneously In a single nucleotide sequence of silencing multiple target miRNAs, the multi-target miRNA antisense nucleotide technology is realized.

specific Embodiment approach 2

[0008] Specific Embodiment 2: The difference between this embodiment and Specific Embodiment 1 is that the number of Step 2 is 2-5. Other steps are the same as in the first embodiment.

specific Embodiment approach 3

[0009] Embodiment 3: The difference between this embodiment and Embodiment 1 is that in step 3, the antisense units of different target miRNAs are designed into a single nucleotide sequence that can simultaneously silence multiple target miRNAs by the following method of: An eight-nucleotide chain is used to connect the antisense units of two different target miRNAs, and the two ends of the eight-nucleotide chain are respectively connected to the 5' of the antisense units of two different target miRNAs and 3', the five nucleotides at both ends of the antisense unit are locked by methylene bridges. Other steps are the same as in the first embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a technology of multi-target miRNA antisense nucleotide, relating to an antisense nucleotide technology. The invention is capable to solve the problems of existing method for silencing miRNAs, e.g. single target and poor action efficacy. The technology of multi-target miRNA antisense nucleotide is achieved by the following procedures: 1. miRNA that capable to regulate the key gene (i.e. pathogenic gene) is found through gene chip screening or provision of documentation; 2. a plurality of antisense miRNA antisense nucleotides are designed into a single-nucleotide sequence that can silence a plurality of multi-target miRNAs, i.e. the technology of multi-target miRNA antisense nucleotide is achieved. The invention can be used as a simple and direct method to conduct study on the bioprocess containing various miRNAs and genes. Compared with existing methods, the greatest advantage of CAMO method lies in that one drug molecule is capable to regulate multi-target genes and the action efficacy is stronger. The invention can well settle the problems of existing methods, i.e. single target and poor action efficacy.

Description

technical field [0001] The invention relates to an antisense nucleotide technology. Background technique [0002] Antisense nucleotide is a synthetic RNA or DNA molecule that specifically binds to mRNA or DNA to block its gene expression. Antisense nucleotides can specifically inhibit cell proliferation and virus replication by blocking or inhibiting key coding genes of tumor cells and viruses, and are new drugs for treating tumors, viral diseases and other related diseases. Currently, there are more than 10 kinds of antisense nucleotide drugs under research, of which 7 have anti-tumor effects, 1 has anti-viral effects, and 4 others have effects on cardiovascular, metabolic, immune and cell adhesion systems. kind. The occurrence of diseases is often the result of the comprehensive action of several or more genes. At present, these antisense nucleotide drug designs are all aimed at a single disease-causing gene or a key sequence that regulates viral gene protein expression ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11C07H21/02A61K31/7088C12N15/113
Inventor 杨宝峰王志国吕延杰白云龙初文峰
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap